EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy

Haosheng Feng iD, Bin Liu iD

Antibody Therapeutics · 01.10.2026 · 9 (4) · 566-575

DOI: 10.1093/abt/tbag042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 18.08.2026. Verfasst von Haosheng Feng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, Multi-Investigator Research Award PILOT PROJECTS, University of Houston.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional antibody–drug conjugates (ADCs) are typically limited to drug-to-antibody ratios (DARs) of ≤8 because of restricted conjugation sites and unfavorable physicochemical properties at higher DARs, including increased hydrophobicity, aggregation, and rapid systemic clearance. Consequently, most clinically approved ADCs rely on highly potent cytotoxic payloads (e.g. IC50 < 1 nM), which can result in significant off-target toxicities. This mini-review summarizes recent advances in next-generation ultrahigh-DAR antibody therapeutics, with a particular focus on two emerging platforms: antibody polymer conjugates (APCs) and antibody–nanoparticle conjugates (ANCs). We discuss their design principles, structural features, and strategies for achieving high payload loading while preserving antigen recognition and favorable pharmacokinetic properties. Recent advances in APCs and ANCs demonstrate that polymer and nanomaterial engineering can overcome the conventional DAR limitations of ADCs, enabling substantially greater payload loading per targeting antibody without compromising targeting performance. These ultrahigh-DAR platforms also expand the range of deliverable payloads, facilitating the development of therapeutics with diverse mechanisms of action beyond traditional ultrapotent cytotoxic agents. Ultrahigh-DAR antibody therapeutics represent a promising next generation of targeted drug delivery systems. By integrating advances in polymer and nanomaterial engineering, APCs and ANCs have the potential to broaden the therapeutic landscape of antibody-based medicines and enable safer, more effective targeted therapies across a wide range of diseases.

Schlagwörter

Stichwörter der Autor:innen

antibody nanoparticle conjugatesantibody polymer conjugatesantibody–drug conjugatestargeted drug deliveryultrahigh drug-to-antibody ratio

Autor:innen und Institutionen

  • Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204, United States.
  • Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, United States.
  • Department of Chemistry, University of Houston, Houston, TX 77204, United States.
  • Department of Biomedical Engineering, University of Houston, Houston, TX 77204, United States.
  • Program of Materials Science and Engineering, University of Houston, Houston, TX 77204, United States.

ORCID-Profile: Haosheng Feng, Bin Liu

Förderung

  • Cancer Prevention and Research Institute of Texas
  • Multi-Investigator Research Award PILOT PROJECTS
  • University of Houston

Zitieren

APA

Feng, H., & Liu, B. (2026). Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy. Antibody Therapeutics, 9(4), 566-575. https://doi.org/10.1093/abt/tbag042

Vancouver

Feng H, Liu B. Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy. Antibody Therapeutics. 2026;9(4):566-575. doi:10.1093/abt/tbag042

BibTeX
@article{Feng2026,
  author = {Feng, Haosheng and Liu, Bin},
  title = {Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {566--575},
  doi = {10.1093/abt/tbag042}
}
Kostenlos starten →